Health Care • Medicinal Chemicals and Botanical Products
$36.33 ▼ -1.63
(-4.29%)
MKT CAP: $5.10B • VOL: 1.08M
52W L $10 52W H $50
DFTX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $0 | $0 | $0 |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$166.3M | -$103.9M | -$93.9M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$183.8M | -$108.7M | -$95.7M |
| EBITDA (Normalized) | -$166.3M | -$103.9M | -$93.9M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$131.6M | -$79.1M | -$64.4M |
| Capital Expenditures (CapEx) | $0 | $0 | $0 |
| Free Cash Flow (FCF) | -$131.6M | -$79.1M | -$64.4M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | -4.4% |
| Cash & Short-Term Equivalents | $257.8M | $273.7M | — |
| Total Debt (Short + Long Term) | $40.6M | $21.9M | $656.4M |
| Total Stockholders' Equity | $332.3M | $241.4M | $1.35B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR DFTX.